Side-by-side comparison of AI visibility scores, market position, and capabilities
India's first UPI wallet for foreign nationals visiting India; $10.8M raised enabling international visitors to pay at 55M+ merchants without an Indian bank account.
CheqUPI is a Bengaluru-based fintech company operating India's first UPI (Unified Payments Interface)-enabled digital wallet specifically designed for foreign nationals, Non-Resident Indians (NRIs), and Overseas Citizens of India (OCIs) visiting or residing in India — enabling international visitors to pay at 55 million+ registered UPI merchants in India without needing an Indian bank account or phone number. Founded in 2021 and a Y Combinator S23 graduate, CheqUPI raised $10.8 million across three funding rounds, serving an estimated 50,000 travelers annually in a market valued at $652 million.\n\nCheqUPI's solution addresses a significant gap in India's digital payments ecosystem: UPI is ubiquitous across India (replacing cash and cards at most merchants) but requires an Indian bank account linked to an Indian phone number — making it inaccessible to the millions of international visitors and Indian diaspora who travel to India annually. CheqUPI provides a wallet that foreign nationals load with money (via international card or transfer), links to UPI, and works at any QR code payment point across the country. This eliminates the cash exchange and card-not-present limitations that international visitors previously faced.\n\nIn 2025, CheqUPI operates in the cross-border payments and travel fintech market for India visitors. The platform competes with international cards (high forex fees), Western Union, and other payment options for foreign visitors in India for UPI access. The Reserve Bank of India (RBI) has been gradually expanding UPI access for international visitors — a positive regulatory tailwind for CheqUPI's market. India received 9+ million international tourist arrivals in 2024, plus millions of NRI/OCI visits from the Indian diaspora abroad, creating substantial demand for seamless digital payment access. The 2025 strategy focuses on growing adoption among travel booking platforms (airlines, OTAs), expanding the wallet loading options for more international currencies, and building B2B corporate travel partnerships for companies sending employees to India.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.